Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.55
- Piotroski Score 3.00
- Grade Neutral
- Symbol (MRTX)
- Company Mirati Therapeutics, Inc.
- Price $58.70
- Changes Percentage (-0.17%)
- Change -$0.1
- Day Low $58.54
- Day High $58.99
- Year High $64.41
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2024
- Fiscal Year End N/A
- Average Stock Price Target $66.50
- High Stock Price Target $247.00
- Low Stock Price Target $53.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$12.18
- Trailing P/E Ratio -4.8193760262726
- Forward P/E Ratio -4.8193760262726
- P/E Growth -4.8193760262726
- Net Income $-740,867,000
